Zai LabZLAB
Market Cap: $2.06B
About: Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-2306 for treatments across multiple solid tumor types including ovarian and certain types of breast and lung cancers; ZL-2401 which is an antibiotic in a new class of tetracycline derivatives; and ZL-2301 is an oral, small molecule which targets HCC.
Employees: 2,175
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
100% more funds holding in top 10
Funds holding in top 10: 1 [Q1] → 2 (+1) [Q2]
6% more capital invested
Capital invested by funds: $665M [Q1] → $702M (+$36.8M) [Q2]
0.12% less ownership
Funds ownership: 4.19% [Q1] → 4.07% (-0.12%) [Q2]
5% less repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 38
10% less funds holding
Funds holding: 112 [Q1] → 101 (-11) [Q2]
46% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 24
91% less call options, than puts
Call options by funds: $1.6M | Put options by funds: $18.5M
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
JP Morgan Anupam Rama 37% 1-year accuracy 22 / 59 met price target | 83%upside $38 | Overweight Maintained | 12 Jul 2024 |